Wedbush lowered the firm’s price target on Oric Pharmaceuticals to $12 from $14 and keeps an Outperform rating on the shares after the company presented preliminary data from the Phase 1/b trial of ORIC-533, its CD73 inhibitor, in late-line patients with r/r MM. The firm believes the totality of the data presented supports ORIC-533’s combination potential with BCMA- and CD38-targeted therapies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORIC:
- Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- Oric Pharmaceuticals reports Q3 EPS (44c), consensus (46c)
- ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
- ORIC Earnings this Week: How Will it Perform?
